We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis.
- Authors
Fujimoto, Yuki; Ueno, Shikiko; Oda, Kazutaka; Gunda, Nao; Shimomura, Yumi; Nishimura, Yuka; Yamaguchi, Ayami; Kuwano, Akari; Ito, Yuki; Baba, Yusuke; Nishigaki, Aina; Michiwaki, Natsumi; Uchino, Shota; Kurogi, Kayo; Kawano, Yawara; Matsuoka, Masao; Saito, Hideyuki; Okuno, Yutaka; Jono, Hirofumi
- Abstract
Simple Summary: Multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. Twenty-four patients with bortezomib therapy were recruited; eight patients (33.3%) developed diarrhea at day 3 as median. The median measured trough bortezomib concentration at 24 h after first or second dose for patients with or without diarrhea was 0.87 or 0.48 ng/mL, respectively (p = 0.04, Wilcoxon signed rank test). Receiver operation characteristic (ROC) analysis produced the cut-off concentration of 0.857 ng/mL (area under the ROC curve of 0.797, sensitivity of 0.625, specificity of 0.875). In conclusion, this study indicated the possible involvement of serum bortezomib concentration in the emergence of diarrhea in bortezomib therapy in patients with multiple myeloma. (1) Background: multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. (2) Methods: this prospective, observational case-control, and monocentric study was performed with an approval by the Ethics Committee of Kumamoto University Hospital in 2015 (No. 1121) from February 2015 to April 2017. (3) Results: twenty-four patients with bortezomib therapy were recruited; eight patients (33.3%) developed diarrhea at day 3 as median. Median measured trough bortezomib concentration at 24 h after first or second dose for patients with or without diarrhea was 0.87 or 0.48 ng/mL, respectively (p = 0.04, Wilcoxon signed rank test). Receiver operation characteristic (ROC) analysis produced the cut-off concentration of 0.857 ng/mL (area under the ROC curve of 0.797, sensitivity of 0.625, specificity of 0.875). The survival curves between patients with and without diarrhea were similar (p = 0.667); those between patients with higher and lower concentration than median value (0.61 ng/mL) were also similar (p = 0.940). (4) Conclusions: this study indicated the possible involvement of serum bortezomib concentration in the emergence of diarrhea in bortezomib therapy in patients with multiple myeloma.
- Subjects
DIARRHEA; AMYLOIDOSIS; SCIENTIFIC observation; CASE-control method; MANN Whitney U Test; BORTEZOMIB; RISK assessment; MULTIPLE myeloma; RECEIVER operating characteristic curves; LONGITUDINAL method
- Publication
Cancers, 2021, Vol 13, Issue 22, p5674
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13225674